HIV Infection
Conditions
Keywords
tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), pre-exposure prophylaxis (PrEP), Private Pharmacies, Implementation study
Brief summary
This is a funded implementation study designed to evaluate the efficacy of recruiting and retaining high-risk individuals on pre-exposure prophylaxis (PrEP) within multiple private pharmacies (and online platforms in South Africa)
Detailed description
This is a two-stage (formative and implementation) study. It will employ a mixed-method approach-specifically, a divergent parallel design. The study will use the EPIS framework (Exploration, Preparation, Implementation, and Sustainability) as an overarching implementation structure to Formalise stakeholder partnerships and tailor the proposed service delivery models (intervention package) for the implementation context. The study chose EPIS as it considers the multilevel nature of healthcare, organizations within systems, and patient needs. Using the capability, opportunity, and motivation for behaviour (COM-B) change model, the study will assess the readiness of pharmacists, pharmacy nurses, and pharmacy clinics to adopt and implement the service delivery models. The study will use participatory human-centred stakeholder engagement to inform appropriateness, acceptability, and feasibility of the service delivery models, priorities for tailoring, and responsibilities for implementation. As a multi-centre pharmacy-initiated implementation study, the project is designed to assess the feasibility and acceptability of in-pharmacy oral PrEP initiation, and oral PrEP initiation utilizing a virtual model and in-pharmacy administration. Additionally, this study will provide information about tolerability, safety, and preferences on accessing prophylactic HIV services. In the formative phase, cross-sectional data collection will take place, while during the implementation stage, young women and men will be screened and recruited to the study across sites in Gauteng and the Western Cape and will be followed over 13 months (prospective, longitudinal).
Interventions
DRUGTenofovir disoproxil fumarate + lamivudine/emtricitabine (TDF+3TC /FTC)
Tenofovir disoproxil fumarate + emtricitabine/ lamivudine Dosage Formulation: 300 mg / 200 mg (300mg) fixed dose combination tablet Route of Administration: Oral Dosing Instructions: 1 tablet (300/200/ TDF/FTC) daily or (300/300/TDF/3TC) daily
Sponsors
Bill and Melinda Gates Foundation
Professor Francois Venter
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Intervention model description
This is a two-stage (formative and implementation) implementation study. We will employ a mixed-method approach-specifically, a divergent parallel design. We will use the EPIS framework (Exploration, Preparation, Implementation, and Sustainability) as an overarching implementation structure to Formalize stakeholder partnerships and tailor the proposed service delivery models (intervention package) for the implementation context.
Eligibility
Sex/Gender
ALL
Age
18 Years to 35 Years
Healthy volunteers
Yes
Inclusion criteria
* Adult male or female (≥18 and ≤ 35 years old) * HIV negative at the time of study enrolment (as determined by a rapid blood test for HIV 1,2) * Absence of symptoms of acute HIV infection\* * Body weight ≥ 35 kg * Creatinine clearance ≥ 50 mL/min * Willingness to take PrEP as prescribed and to comply with study procedures. * Willingness to be followed up throughout the duration of the study.
Exclusion criteria
* Confirmed HIV positive by routine antibody testing * Presence of symptoms of acute HIV infection\* * Creatinine clearance (eGFR) of: * Less than 50 mL/min/1.73m2 for adults * For pregnant women: serum creatinine (sCr) greater than 85 µmol/L * Known hypersensitivity to or specific contraindications to the use of TDF or FTC/3TC * Self-reported presence or history of liver cirrhosis (Child-Pugh Class B or greater), with or without viral hepatitis co-infection * Any surgical or medical condition which may significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the safety of the participant. This will be an investigator-led determination based on the medical history of the participant. This includes, but is not limited to: • Severe hepatic impairment or history of liver cirrhosis with or without viral hepatitis co-infection. * Participant is judged by the Investigator to be at significant risk of failing to comply with the provisions of the protocol as to cause harm to self or seriously interfere with the validity of the study results. * Inability or unwillingness to be followed up for the study period * Pregnant and lactating women
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of pharmacies providing Prep services over 13 months | 13 Months | Acceptability of pharmacy-delivered PrEP services will be determined by qualitative and quantitative assessment using piloted and validated semi-structured questionnaires for acceptability. |
| Number of participants accessing PrEP online services over 13 months | 13 Months | Acceptability of online-delivered PrEP services will be determined by qualitative and quantitative assessment using piloted and validated semi-structured questionnaires for acceptability. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To describe provider experiences and perceptions of pharmacy and online-delivered PrEP | 13 Months | Provider Perspectives on service delivery using semi-structured interviews using REAIM |
| To describe user experiences and perceptions of pharmacy and online-delivered PrEP | 13 Months | User perspectives on service delivery using semi-structured interviews using REAIM |
Countries
South Africa
Outcome results
None listed